LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Home・Aandelen Lijst・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Gesloten

SectorGezondheidszorg

3.48 -3.33

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.45

Max

3.61

Belangrijke statistieken
By Trading Economics
Inkomsten	8.3M -18M
Verkoop	9.6M 10M
K/W Sectorgemiddelde	22.5 51.415
EPS	-0.1
Winstmarge	-177.89
Werknemers	69
EBITDA	8M -19M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+260.11% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-70M 840M
Vorige openingsprijs	6.81
Vorige sluitingsprijs	3.48

Nieuwssentiment

By Acuity

34%

66%

69 / 345 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

0.7658 / N/A Steun & Weerstand

CytomX Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 mei 2026, 23:53 UTC

Acquisities, Fusies, Overnames

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15 mei 2026, 22:47 UTC

Populaire aandelen

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 mei 2026, 22:16 UTC

Acquisities, Fusies, Overnames

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 mei 2026, 22:00 UTC

Belangrijke Marktbewegers

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 mei 2026, 18:09 UTC

Belangrijke Marktbewegers

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17 mei 2026, 23:50 UTC

Marktinformatie

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17 mei 2026, 23:43 UTC

Marktinformatie

Global Equities Roundup: Market Talk

17 mei 2026, 23:43 UTC

Marktinformatie

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17 mei 2026, 23:36 UTC

Marktinformatie

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17 mei 2026, 23:07 UTC

Acquisities, Fusies, Overnames

UOB: Transactions Part of Group's Capital Reallocation Strategy

17 mei 2026, 23:06 UTC

Acquisities, Fusies, Overnames

UOB: Share Sale Agreements Entered With Singland Properties

17 mei 2026, 23:05 UTC

Acquisities, Fusies, Overnames

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17 mei 2026, 22:31 UTC

Acquisities, Fusies, Overnames

Prudential PLC to Fund Stake Acquisition via Internal Resources

17 mei 2026, 22:31 UTC

Acquisities, Fusies, Overnames

Prudential PLC to Acquire Stake for $389 Million

17 mei 2026, 22:30 UTC

Acquisities, Fusies, Overnames

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16 mei 2026, 16:27 UTC

Acquisities, Fusies, Overnames

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 mei 2026, 15:26 UTC

Acquisities, Fusies, Overnames

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16 mei 2026, 08:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

15 mei 2026, 22:17 UTC

Acquisities, Fusies, Overnames

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mei 2026, 21:59 UTC

Acquisities, Fusies, Overnames

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 mei 2026, 21:50 UTC

Acquisities, Fusies, Overnames

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mei 2026, 21:30 UTC

Acquisities, Fusies, Overnames

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 mei 2026, 21:16 UTC

Marktinformatie

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 mei 2026, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

15 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

15 mei 2026, 20:19 UTC

Populaire aandelen

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 mei 2026, 19:41 UTC

Acquisities, Fusies, Overnames

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 mei 2026, 19:35 UTC

Marktinformatie

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 mei 2026, 19:33 UTC

Marktinformatie

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 mei 2026, 18:35 UTC

Winsten

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Peer Vergelijking

Prijswijziging

CytomX Therapeutics Inc Prognose

Koersdoel

By TipRanks

260.11% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 13 USD 260.11%

Hoogste 16 USD

Laagste 11 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor CytomX Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan CytomX Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.7658 / N/ASteun & Weerstand

Bullish events outweigh bearish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

69 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.